Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

axc

  • Home
  •  
  • axc



  • Most Read
  • Latest Comments
  • Invex randomises the first patient for phase III trial of its IIH drug
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Invex randomises the first patient for phase III trial of its IIH drug
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Invex randomises the first patient for phase III trial of its IIH drug
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Invex randomises the first patient for phase III trial of its IIH drug
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Invex randomises the first patient for phase III trial of its IIH drug
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Invex struggles to recruit patients, witnesses test failures for its clinical trial for intracranial hypertension alleviating drug
    Invex struggles to recruit patients, witnesses test failures for its clinical trial for intracranial hypertension alleviating drug
    • News

  • Invex randomises the first patient for phase III trial of its IIH drug
    Invex randomises the first patient for phase III trial of its IIH drug
    • News

  • Uscom hits jackpot with China approval for hypertension monitor
    Uscom hits jackpot with China approval for hypertension monitor
    • News

  • Invex randomises the first patient for phase III trial of its IIH drug
    • News

    Invex randomises the first patient for phase III trial of its IIH drug

    Imagine a headache so intense that the literal ear-throbbing pain results in blindness or other vision impairments. Even though sometimes it may not be so extreme, Idiopathic Intracranial Hypertension (IIH) can take such a form, making it integral to develop a cure for the same. Invex (ASX: IXC) believes that it has got one with

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.